ClinicalTrials.gg
CompletedNCT00505687Updated Oct 2, 2014Results posted

An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease

A Phase 3 interventional study of Rotigotine in Idiopathic Parkinson's Disease, sponsored by UCB Pharma. Completed at 26 sites in 8 countries. Open to participants aged 31 Years and older. Per ClinicalTrials.gov, last updated 2014-10-02.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
186
Allocation
Not applicable
Ages
31 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
15th of 42
186 · median 123
Started
2005
with 1 other
Phase 3
20 of 44
none open now
Registered
9th of 44
by date
Lead sponsor
22 of 44
UCB Pharma

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 15th largest by enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2005, is one of 20 in phase 3, and was the 9th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 31 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of rotigotine in subjects with idiopathic PD.

Read the detailed description

This is the open-label extension to the open-label trials SP824 (NCT00242008), SP825 (NCT00243971), and SP826 (NCT00243945) that assessed the efficacy and safety and tolerability of rotigotine in subjects with idiopathic Parkinson's Disease.

03

Conditions studied

  • Idiopathic Parkinson's Disease

Browse trials for

Keywords

  • Rotigotine
  • Neupro®
04

Who can participate

Ages eligible
31 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have completed treatment in one of the SP824 (NCT00242008), SP825 (NCT00243971), or SP826 (NCT00243945) trials

Exclusion criteria

Exclusion Criteria:

  • Subjects who had an ongoing serious adverse event from the previous OLE trial that was assessed as related to study medication
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
186 participants (actual)

Study arms

  • Experimental
    Rotigotine

    Rotigotine

    Drug: Rotigotine

Interventions

  • Rotigotine transdermal patches: 10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) Optimal dosing: The maximum rotigotine dose allowed is 16 mg/24 hours.

    Also known as: Neupro

06

What researchers measure

Primary outcomes

  1. Number of Subjects With at Least One Adverse Event During This Open-label Extension Study

    Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

    Time frame: four years

Secondary outcomes

  1. Number of Subjects Who Withdrew From the Trial Due to an Adverse Event

    Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

    Time frame: four years

  2. Mean Epworth Sleepiness Scale Score During the Open-label Extension.

    The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness.

    Time frame: Visit 6 (post year 1), Visit 10 (post year 2), Visit 14 (post year 3), End of Treatment (last study visit or early withdrawal visit)

07

Results

Posted Jan 12, 2010

Participant flow

An Open-Label Extension Trial to Assess the Safety and Tolerability of Long-term Treatment of Rotigotine in Subjects with Idiopathic Parkinson's Disease in 26 locations from February 2005 to December 2008.

Participant flow — Overall Study
MilestoneRotigotine
Started186
Completed91
Not completed95
Withdrew: Important protocol violation2
Withdrew: Lack of efficacy15
Withdrew: Adverse event48
Withdrew: Subject withdrew consent15
Withdrew: Lost to follow-up1
Withdrew: Other: underwent implantation of dbs1
Withdrew: Other: scheduled dbs surgery1
Withdrew: Other: prolonged hospitalization1
Withdrew: Other: patches would not stick d/t sweat1
Withdrew: Other: neupro given in hospital1
Withdrew: Other: disease progression1
Withdrew: Other: as per sponsor8

Outcome measures

PrimaryNumber of Subjects With at Least One Adverse Event During This Open-label Extension Study

Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

Time frame:
four years
Reported as:
Number · Subjects
Number of Subjects With at Least One Adverse Event During This Open-label Extension Study
SubjectsRotigotine
Number of Subjects With at Least One Adverse Event During This Open-label Extension Study170
SecondaryNumber of Subjects Who Withdrew From the Trial Due to an Adverse Event

Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

Time frame:
four years
Reported as:
Number · Subjects
Number of Subjects Who Withdrew From the Trial Due to an Adverse Event
SubjectsRotigotine
Number of Subjects Who Withdrew From the Trial Due to an Adverse Event48
SecondaryMean Epworth Sleepiness Scale Score During the Open-label Extension.

The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness.

Time frame:
Visit 6 (post year 1), Visit 10 (post year 2), Visit 14 (post year 3), End of Treatment (last study visit or early withdrawal visit)
Reported as:
Mean · Score on a scale
Mean Epworth Sleepiness Scale Score During the Open-label Extension.
Score on a scaleRotigotine
Visit 6 (post year 1) (n=164)9.3 ± 5.6
Visit 10 (post year 2) (n=164)10.0 ± 5.9
Visit 14 (post year 3) (n=164)10.3 ± 6.1
End of Treatment (n=182)10.1 ± 5.9

Adverse events

Collected over up to four years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rotigotine—45/186 (24.2%)136/186 (73.1%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventRotigotine
OsteoarthritisMusculoskeletal and connective tissue disorders3/186
Parkinson's diseaseNervous system disorders3/186
CellulitisInfections and infestations2/186
FallInjury, poisoning and procedural complications2/186
ArthralgiaMusculoskeletal and connective tissue disorders2/186
ParkinsonismNervous system disorders2/186
SyncopeNervous system disorders2/186
AnaemiaBlood and lymphatic system disorders1/186
Angina pectorisCardiac disorders1/186
Myocardial infarctionCardiac disorders1/186
Most frequent other events
Showing 10 of 20
Most frequent other events
EventRotigotine
SomnolenceNervous system disorders52/186
Oedema peripheralGeneral disorders36/186
FallInjury, poisoning and procedural complications29/186
Application site erythemaGeneral disorders24/186
InsomniaPsychiatric disorders24/186
NauseaGastrointestinal disorders21/186
Back painMusculoskeletal and connective tissue disorders21/186
DepressionPsychiatric disorders19/186
DizzinessNervous system disorders18/186
Application site pruritusGeneral disorders16/186

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rotigotine
<=18 years0
Between 18 and 65 years94
>=65 years92
Age, Continuous
Age, Continuous(years)Rotigotine
Mean62.5 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Rotigotine
Female60
Male126
Region of Enrollment
Region of Enrollment(participants)Rotigotine
United States80
Spain9
Austria4
South Africa22
Israel20
Germany22
United Kingdom20
Italy9
08

Study locations

26 sites
  • Birmingham, Alabama, United States
  • St. Petersburg, Florida, United States
  • Fort Wayne, Indiana, United States
  • Southfield, Michigan, United States
  • Forest Hills, New York, United States
  • Asheville, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Houston, Texas, United States
  • Milwaukee, Wisconsin, United States
  • Innsbruck, 6020, Austria
  • Bochum, Germany
  • Dresden, Germany
  • Kassel, Germany
  • Ulm, Germany
  • Tel Aviv, Israel
  • Ancona, Italy
  • Lucca, Italy
  • Messina, Italy
  • Pretoria, Gauteng, South Africa
  • Parow, Western Cape, South Africa
  • Plumstead, Western Cape, South Africa
  • Barcelona, Spain
  • Barncose Terrace, Redruth, United Kingdom
  • Bridgend, United Kingdom
  • North Shields, United Kingdom
  • Tyne and Wear, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2007
First posted
Jul 23, 2007
Start
Feb 2005
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Jan 12, 2010
Last update
Oct 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00505687
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Jul 23, 2007
Start date
Feb 2005
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Jan 12, 2010
Last update
Oct 2, 2014

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion